iVeena
Ned M. Weinshenker, Ph.D, recently retired from Utah State University where he was Vice President for Strategic Ventures and Economic Development. He is currently President of Churchill Oaks Consulting, a firm he started over 30 years ago where he provided management and technical consulting to a range of clients in the pharmaceutical, biotechnology and diagnostics, as well as venture capital funds in those areas.
Dr. Weinshenker has over 42 years of business, education and scientific expertise. Before joining Utah State University he was the Director of the Life Sciences Cluster in the Utah Governor’s Office of Economic Development. He served in upper management positions at several Silicon Valley biotechnology and venture capital firms, and was President, CEO and Director for Salt Lake City-based IOMED, where he was responsible for the creation of new products, partnerships, and overseeing a successful IPO in 1998. He served as President and CEO of two University of Utah spin-outs, MantiCore Pharmaceuticals and Pharmadigm. Previous positions were at ALZA Corporation, Liposome Technology and MBW Management.
Dr. Weinshenker worked as an Assistant Professor in the University of Maryland’s Department of Chemistry, and has been an Invited Lecturer and Visiting Scholar at Stanford University. He also was a member of Westminster College’s School of Business Technology and Entrepreneur Advisory Board, the Advisory Council for Utah Centers of Excellence Program, and the University of Utah’s College of Science Advisory Committee.
Dr. Weinshenker received a B.Sc. at the Polytechnic Institute of Brooklyn, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology under A.C. Cope, and was an NIH Postdoctoral Fellow at Harvard University under Nobel Laureate E.J. Corey.
This person is not in any offices
iVeena
Keratoconus, progressive myopia, and development of cystoid macular edema are areas of major unmet medical need. iVeena is developing two platform technologies in cornea and cataract — including topical delivery of copper and drug delivery from the lens capsule respectively. These novel approaches provide impactful and minimally invasive solutions for patients and physicians.